Literature DB >> 3122788

Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City.

M Marmor1, D C Des Jarlais, H Cohen, S R Friedman, S T Beatrice, N Dubin, W el-Sadr, D Mildvan, S Yancovitz, U Mathur.   

Abstract

We report here the results of a survey of 308 intravenous drug abusers recruited from hospital-based methadone maintenance or drug detoxification programmes located in Manhattan, New York City. Complete interviews and serological analyses for antibodies to human immunodeficiency virus (HIV) using both enzyme-linked immunosorbent and Western blot assays were obtained from 290 (94%) of the subjects. HIV antibodies were found by both assays in 147 (50.7%) of the tested subjects; conflicting results were found in three (1%) of the subjects; and negative results on both tests were found in 140 (48.3%) of the subjects. Logistic regression analysis identified significant relative risks for HIV infection associated with the frequency of drug injection and the proportion of injections in 'shooting galleries'. Additional risk among men was associated with a history of homosexual relations. Traditional efforts taken by subjects to clean syringes between uses, such as washing with water or alcohol, showed no evidence of being protective. Programmes aimed at prevention of HIV infection should focus on reducing use of shooting galleries and sharing of needles and syringes as well as reducing intravenous drug abuse generally.

Entities:  

Mesh:

Year:  1987        PMID: 3122788

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  44 in total

1.  Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990-1999.

Authors:  Carey B Maslow; Samuel R Friedman; Theresa E Perlis; Russell Rockwell; Don C Des Jarlais
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

2.  Determinants of HIV prevalence amongst female IDU in Madrid.

Authors:  P Estébanez; N K Russell; M D Aguilar; I Cifuentes; M V Zunzunegui; K McPherson
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  Sex-specific determinants of HIV infection among injection drug users in Montreal.

Authors:  J Bruneau; F Lamothe; J Soto; N Lachance; J Vincelette; A Vassal; E L Franco
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

4.  Prevalence and predictors of transitions to and away from syringe exchange use over time in 3 US cities with varied syringe dispensing policies.

Authors:  Traci C Green; Ricky N Bluthenthal; Merrill Singer; Leo Beletsky; Lauretta E Grau; Patricia Marshall; Robert Heimer
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

5.  Explaining the geographical variation of HIV among injection drug users in the United States.

Authors:  D Ciccarone; P Bourgois
Journal:  Subst Use Misuse       Date:  2003-12       Impact factor: 2.164

6.  Shooting gallery operation in the context of establishing a medically supervised injecting center: Sydney, Australia.

Authors:  Jo Kimber; Kate Dolan
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

Review 7.  Maintenance of endemicity in urban environments: a hypothesis linking risk, network structure and geography.

Authors:  R Rothenberg
Journal:  Sex Transm Infect       Date:  2007-02       Impact factor: 3.519

8.  AIDS, HIV infection, and illicit drug use within inner-city families and social networks.

Authors:  A Pivnick; A Jacobson; K Eric; L Doll; E Drucker
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

9.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.

Authors:  D M Hartel; E E Schoenbaum
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 10.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.